The University of Chicago Header Logo

Connection

Stuart Sprague to Humans

Back to Details
This is a "connection" page, showing publications Stuart Sprague has written about Humans.
Stuart Sprague
Connection Strength
1.188
Humans
  1. Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial. Am J Nephrol. 2026; 57(1):109-119.
    View in: PubMed
    Score: 0.030
  2. An update on investigation and management of renal bone disease. Curr Opin Endocrinol Diabetes Obes. 2025 Aug 01; 32(4):135-141.
    View in: PubMed
    Score: 0.029
  3. Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE study. Curr Med Res Opin. 2024 Aug; 40(8):1335-1343.
    View in: PubMed
    Score: 0.028
  4. Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study. Kidney360. 2024 05 01; 5(5):732-742.
    View in: PubMed
    Score: 0.027
  5. Serum Phosphorus Management with Sucroferric Oxyhydroxide as a First-Line Phosphate Binder within the First Year of Hemodialysis. Am J Nephrol. 2024; 55(2):127-135.
    View in: PubMed
    Score: 0.027
  6. Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and Diet. Kidney360. 2023 11 01; 4(11):1650-1656.
    View in: PubMed
    Score: 0.027
  7. High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders. Am J Nephrol. 2023; 54(5-6):219-223.
    View in: PubMed
    Score: 0.026
  8. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Drug Saf. 2021 Dec; 20(12):1463-1472.
    View in: PubMed
    Score: 0.023
  9. Small Intestinal Phosphate Absorption: Novel Therapeutic Implications. Am J Nephrol. 2021; 52(7):522-530.
    View in: PubMed
    Score: 0.023
  10. Secondary Hyperparathyroidism in a Patient with CKD. Clin J Am Soc Nephrol. 2020 07 01; 15(7):1041-1043.
    View in: PubMed
    Score: 0.021
  11. Interventions for Preventing Bone Disease Following Kidney Transplantation: Is There Evidence for Specific Therapy? Am J Kidney Dis. 2020 05; 75(5):809-811.
    View in: PubMed
    Score: 0.021
  12. Cortical Perfusion and Tubular Function as Evaluated by Magnetic Resonance Imaging Correlates with Annual Loss in Renal Function in Moderate Chronic Kidney Disease. Am J Nephrol. 2019; 49(2):114-124.
    View in: PubMed
    Score: 0.019
  13. Mineral and Bone Disease in Kidney Transplant Recipients. Curr Osteoporos Rep. 2018 12; 16(6):703-711.
    View in: PubMed
    Score: 0.019
  14. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Pharmacother. 2018 Jul; 19(10):1137-1148.
    View in: PubMed
    Score: 0.018
  15. Should phosphate management be limited to the KDIGO/ KDOQI guidelines? Semin Dial. 2018 07; 31(4):377-381.
    View in: PubMed
    Score: 0.018
  16. Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. Hemodial Int. 2018 10; 22(4):480-491.
    View in: PubMed
    Score: 0.018
  17. Factors associated with health-related quality of life, hip function, and health utility after operative management of femoral neck fractures. Bone Joint J. 2018 03 01; 100-B(3):361-369.
    View in: PubMed
    Score: 0.018
  18. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data?. Clin Nephrol. 2017 Aug; 88(8):59-67.
    View in: PubMed
    Score: 0.017
  19. Imaging in Chronic Kidney Disease-Metabolic Bone Disease. Semin Dial. 2017 07; 30(4):361-368.
    View in: PubMed
    Score: 0.017
  20. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Am J Nephrol. 2016; 44(4):316-325.
    View in: PubMed
    Score: 0.016
  21. Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients. Am J Nephrol. 2016; 44(2):104-12.
    View in: PubMed
    Score: 0.016
  22. We Do Too Many Parathyroidectomies for Calciphylaxis. Semin Dial. 2016 07; 29(4):312-4.
    View in: PubMed
    Score: 0.016
  23. Multi-Parametric Evaluation of Chronic Kidney Disease by MRI: A Preliminary Cross-Sectional Study. PLoS One. 2015; 10(10):e0139661.
    View in: PubMed
    Score: 0.015
  24. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis. 2016 Apr; 67(4):559-66.
    View in: PubMed
    Score: 0.015
  25. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1021-30.
    View in: PubMed
    Score: 0.015
  26. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol. 2014; 40(6):535-45.
    View in: PubMed
    Score: 0.014
  27. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol. 2014 Sep 05; 9(9):1620-6.
    View in: PubMed
    Score: 0.014
  28. Painful skin ulcers in a hemodialysis patient. Clin J Am Soc Nephrol. 2014 Jan; 9(1):166-73.
    View in: PubMed
    Score: 0.013
  29. Women and CKD-mineral and bone disorder. Adv Chronic Kidney Dis. 2013 Sep; 20(5):423-6.
    View in: PubMed
    Score: 0.013
  30. Rebuttal: PTH--a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol. 2013 Feb; 8(2):321.
    View in: PubMed
    Score: 0.012
  31. CKD-mineral and bone disorder management in kidney transplant recipients. Am J Kidney Dis. 2013 Feb; 61(2):310-25.
    View in: PubMed
    Score: 0.012
  32. The case for routine parathyroid hormone monitoring. Clin J Am Soc Nephrol. 2013 Feb; 8(2):313-8.
    View in: PubMed
    Score: 0.012
  33. Impact of CKD on coronary artery calcifications. Am J Kidney Dis. 2011 Oct; 58(4):503-5.
    View in: PubMed
    Score: 0.012
  34. Is bone mineral density measurement of any value in a dialysis patient? Semin Dial. 2011 Jul-Aug; 24(4):433-4.
    View in: PubMed
    Score: 0.011
  35. Renal bone disease. Curr Opin Endocrinol Diabetes Obes. 2010 Dec; 17(6):535-9.
    View in: PubMed
    Score: 0.011
  36. Evaluation of cinacalcet HCl treatment after kidney transplantation. Transplant Proc. 2010 Sep; 42(7):2503-8.
    View in: PubMed
    Score: 0.011
  37. Use of vitamin D in chronic kidney disease patients. Kidney Int. 2010 Jul; 78(2):146-51.
    View in: PubMed
    Score: 0.011
  38. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. Clin J Am Soc Nephrol. 2010 Mar; 5(3):512-8.
    View in: PubMed
    Score: 0.010
  39. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol. 2009 Oct; 72(4):252-8.
    View in: PubMed
    Score: 0.010
  40. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol. 2009 Sep; 4(9):1465-76.
    View in: PubMed
    Score: 0.010
  41. Advances in renal bone disease: osteoporosis and chronic kidney disease. Curr Rheumatol Rep. 2009 Jul; 11(3):185-90.
    View in: PubMed
    Score: 0.010
  42. When is Vitamin D contraindicated in dialysis patients? Semin Dial. 2009 May-Jun; 22(3):249-51.
    View in: PubMed
    Score: 0.010
  43. Bone disease in kidney transplant patients. Semin Nephrol. 2009 Mar; 29(2):166-73.
    View in: PubMed
    Score: 0.010
  44. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009 Jan; 4(1):178-85.
    View in: PubMed
    Score: 0.010
  45. Role of bone biopsy in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol. 2008 Nov; 3 Suppl 3:S170-4.
    View in: PubMed
    Score: 0.009
  46. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr Pract. 2008 Jan-Feb; 14(1):18-27.
    View in: PubMed
    Score: 0.009
  47. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin. 2007 Dec; 23(12):3167-75.
    View in: PubMed
    Score: 0.009
  48. Role of vitamin D deficiency in chronic kidney disease. J Bone Miner Res. 2007 Dec; 22 Suppl 2:V91-4.
    View in: PubMed
    Score: 0.009
  49. Abnormal bone and mineral metabolism in kidney transplant patients--a review. Am J Nephrol. 2008; 28(2):246-53.
    View in: PubMed
    Score: 0.009
  50. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol. 2008; 28(1):97-106.
    View in: PubMed
    Score: 0.009
  51. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2007 Oct; 72(7):895; author reply 895-6.
    View in: PubMed
    Score: 0.009
  52. Osteoporosis and chronic kidney disease. Semin Dial. 2007 Sep-Oct; 20(5):423-30.
    View in: PubMed
    Score: 0.009
  53. Clinical and economic burden of fractures in patients with renal osteodystrophy. Clin Nephrol. 2007 Apr; 67(4):201-8.
    View in: PubMed
    Score: 0.008
  54. Renal function and risk of hip and vertebral fractures in older women: is it always osteoporosis? Arch Intern Med. 2007 Jan 22; 167(2):115-6.
    View in: PubMed
    Score: 0.008
  55. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007; 27(1):36-43.
    View in: PubMed
    Score: 0.008
  56. Bone health in chronic kidney disease-mineral and bone disease. Adv Chronic Kidney Dis. 2007 Jan; 14(1):27-36.
    View in: PubMed
    Score: 0.008
  57. Comparative cost-benefit analyses of paricalcitol and calcitriol in stage 4 chronic kidney disease from the perspective of a health plan. Clin Drug Investig. 2007; 27(2):105-13.
    View in: PubMed
    Score: 0.008
  58. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006 Feb; 47(2):263-76.
    View in: PubMed
    Score: 0.008
  59. Bone disease after kidney transplantation. Adv Chronic Kidney Dis. 2006 Jan; 13(1):35-46.
    View in: PubMed
    Score: 0.008
  60. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol. 2005 Nov-Dec; 25(6):591-5.
    View in: PubMed
    Score: 0.008
  61. Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial. Am J Nephrol. 2025; 56(4):490-499.
    View in: PubMed
    Score: 0.007
  62. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation. 2004 Oct 27; 78(8):1233-6.
    View in: PubMed
    Score: 0.007
  63. Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients With Kidney Failure. J Ren Nutr. 2025 Jan; 35(1):25-34.
    View in: PubMed
    Score: 0.007
  64. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. Adv Ther. 2024 Jun; 41(6):2500-2518.
    View in: PubMed
    Score: 0.007
  65. Associations of Kidney Functional Magnetic Resonance Imaging Biomarkers with Markers of Inflammation in Individuals with CKD. Kidney360. 2024 05 01; 5(5):681-689.
    View in: PubMed
    Score: 0.007
  66. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004 May; 19(5):1174-81.
    View in: PubMed
    Score: 0.007
  67. Bone disease after kidney transplantation. Semin Nephrol. 2004 Jan; 24(1):82-90.
    View in: PubMed
    Score: 0.007
  68. Oral Sodium Bicarbonate and Bone Turnover in CKD: A Secondary Analysis of the BASE Pilot Trial. J Am Soc Nephrol. 2024 01 01; 35(1):57-65.
    View in: PubMed
    Score: 0.007
  69. Dialysis-related amyloidosis. Minerva Urol Nefrol. 2003 Jun; 55(2):121-9.
    View in: PubMed
    Score: 0.006
  70. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003 Apr; 63(4):1483-90.
    View in: PubMed
    Score: 0.006
  71. Renal osteodystrophy in chronic renal failure. Semin Nephrol. 2002 Nov; 22(6):488-93.
    View in: PubMed
    Score: 0.006
  72. Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient. Clin Nephrol. 2002 Aug; 58(2):155-60.
    View in: PubMed
    Score: 0.006
  73. The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Secondary and Tertiary Renal Hyperparathyroidism. Ann Surg. 2022 09 01; 276(3):e141-e176.
    View in: PubMed
    Score: 0.006
  74. Use of vitamin D analogs in chronic renal failure. Adv Ren Replace Ther. 2002 Jul; 9(3):175-83.
    View in: PubMed
    Score: 0.006
  75. Percutaneous bone biopsy in the diagnosis of renal osteodystrophy. Semin Nephrol. 2002 May; 22(3):268-75.
    View in: PubMed
    Score: 0.006
  76. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence. J Nephrol. 2022 04; 35(3):875-888.
    View in: PubMed
    Score: 0.006
  77. Abnormalities in Cardiac Structure and Function among Individuals with CKD: The COMBINE Trial. Kidney360. 2022 02 24; 3(2):258-268.
    View in: PubMed
    Score: 0.006
  78. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis. 2001 Nov; 38(5 Suppl 5):S51-6.
    View in: PubMed
    Score: 0.006
  79. Beta(2)-microglobulin and bone cell metabolism. Nephrol Dial Transplant. 2001 Jun; 16(6):1108-11.
    View in: PubMed
    Score: 0.006
  80. The pathogenesis of beta(2)-microglobulin-induced bone lesions in dialysis-related amyloidosis. Semin Dial. 2001 Mar-Apr; 14(2):131-3.
    View in: PubMed
    Score: 0.006
  81. Medullary Blood Oxygen Level-Dependent MRI Index (R2*) is Associated with Annual Loss of Kidney Function in Moderate CKD. Am J Nephrol. 2020; 51(12):966-974.
    View in: PubMed
    Score: 0.006
  82. Mechanism of transplantation-associated bone loss. Pediatr Nephrol. 2000 Jul; 14(7):650-3.
    View in: PubMed
    Score: 0.005
  83. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Nephron. 2020; 144(9):428-439.
    View in: PubMed
    Score: 0.005
  84. The role of the bone biopsy in the diagnosis of renal osteodystrophy. Semin Dial. 2000 May-Jun; 13(3):152-5.
    View in: PubMed
    Score: 0.005
  85. Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD. Clin J Am Soc Nephrol. 2020 06 08; 15(6):776-783.
    View in: PubMed
    Score: 0.005
  86. A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial. J Am Soc Nephrol. 2020 01; 31(1):161-174.
    View in: PubMed
    Score: 0.005
  87. Renal BOLD MRI in patients with chronic kidney disease: comparison of the semi-automated twelve layer concentric objects (TLCO) and manual ROI methods. MAGMA. 2020 Feb; 33(1):113-120.
    View in: PubMed
    Score: 0.005
  88. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol Dial Transplant. 2019 07 01; 34(7):1163-1170.
    View in: PubMed
    Score: 0.005
  89. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. Kidney Int. 2019 10; 96(4):1030-1036.
    View in: PubMed
    Score: 0.005
  90. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. J Am Soc Nephrol. 2019 06; 30(6):1096-1108.
    View in: PubMed
    Score: 0.005
  91. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease. Am J Nephrol. 2019; 49(4):284-293.
    View in: PubMed
    Score: 0.005
  92. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res. 1999 Mar; 14(3):456-63.
    View in: PubMed
    Score: 0.005
  93. Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. J Diabetes Complications. 2018 Dec; 32(12):1113-1117.
    View in: PubMed
    Score: 0.005
  94. Consistency of Multiple Renal Functional MRI Measurements Over 18 Months. J Magn Reson Imaging. 2018 08; 48(2):514-521.
    View in: PubMed
    Score: 0.005
  95. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrol Dial Transplant. 2017 Nov 01; 32(11):1918-1926.
    View in: PubMed
    Score: 0.004
  96. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplant. 2017 Aug 01; 32(8):1330-1338.
    View in: PubMed
    Score: 0.004
  97. Perspective and priorities for improvement of parathyroid hormone (PTH) measurement - A view from the IFCC Working Group for PTH. Clin Chim Acta. 2017 Apr; 467:42-47.
    View in: PubMed
    Score: 0.004
  98. Advanced glycation of beta 2-microglobulin in the pathogenesis of bone lesions in dialysis-associated amyloidosis. Nephrol Dial Transplant. 1996; 11 Suppl 3:86-90.
    View in: PubMed
    Score: 0.004
  99. Possible involvement of advanced glycation end-products in bone resorption. Nephrol Dial Transplant. 1996; 11 Suppl 5:54-7.
    View in: PubMed
    Score: 0.004
  100. Renal Blood Oxygenation Level-Dependent Magnetic Resonance Imaging: A Sensitive and Objective Analysis. Invest Radiol. 2015 Dec; 50(12):821-7.
    View in: PubMed
    Score: 0.004
  101. Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. J Am Soc Nephrol. 2015 Oct; 26(10):2328-39.
    View in: PubMed
    Score: 0.004
  102. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1031-40.
    View in: PubMed
    Score: 0.004
  103. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. J Nephrol. 2016 Feb; 29(1):63-70.
    View in: PubMed
    Score: 0.004
  104. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015 Jun; 30(6):1037-46.
    View in: PubMed
    Score: 0.004
  105. Is beta 2-microglobulin a mediator of bone disease? Kidney Int. 1995 Jan; 47(1):1-6.
    View in: PubMed
    Score: 0.004
  106. Uremic encephalopathy. Clin Nephrol. 1994 Oct; 42(4):251-6.
    View in: PubMed
    Score: 0.004
  107. Hypocalcemia in end-stage renal disease: a consequence of spontaneous parathyroid gland infarction. Am J Kidney Dis. 1994 Sep; 24(3):519-22.
    View in: PubMed
    Score: 0.004
  108. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014 Sep; 86(3):638-47.
    View in: PubMed
    Score: 0.003
  109. A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease. Artif Organs. 2014 Jun; 38(6):474-83.
    View in: PubMed
    Score: 0.003
  110. Maintenance of bone mass in patients receiving dialytic therapy. Am J Kidney Dis. 1993 Aug; 22(2):300-7.
    View in: PubMed
    Score: 0.003
  111. Impact of serum source and inflammatory cytokines on the isolation of endothelial colony-forming cells from peripheral blood. J Tissue Eng Regen Med. 2014 Sep; 8(9):747-56.
    View in: PubMed
    Score: 0.003
  112. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis. 1992 Jun; 19(6):532-9.
    View in: PubMed
    Score: 0.003
  113. Serum amyloid P component: a predictor of clinical beta 2-microglobulin amyloidosis. Am J Kidney Dis. 1992 May; 19(5):427-32.
    View in: PubMed
    Score: 0.003
  114. Variation in parathyroid hormone immunoassay results--a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant. 2011 Nov; 26(11):3440-5.
    View in: PubMed
    Score: 0.003
  115. Aluminum neurotoxicity: a reevaluation. Clin Neuropharmacol. 1991 Apr; 14(2):179-85.
    View in: PubMed
    Score: 0.003
  116. Early tissue response to citric acid-based micro- and nanocomposites. J Biomed Mater Res A. 2011 Jan; 96(1):29-37.
    View in: PubMed
    Score: 0.003
  117. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010 May; 55(5):773-99.
    View in: PubMed
    Score: 0.003
  118. Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodial Int. 2010 Apr; 14(2):182-92.
    View in: PubMed
    Score: 0.003
  119. Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr. 2010 Jul; 20(4):243-54.
    View in: PubMed
    Score: 0.003
  120. Relationship of aluminum to neurocognitive dysfunction in chronic dialysis patients. Arch Intern Med. 1988 Oct; 148(10):2169-72.
    View in: PubMed
    Score: 0.002
  121. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol. 2008 Sep; 3(5):1437-45.
    View in: PubMed
    Score: 0.002
  122. Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed? Semin Dial. 2007 Jan-Feb; 20(1):24-32.
    View in: PubMed
    Score: 0.002
  123. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. Arch Intern Med. 1986 Oct; 146(10):2063-4.
    View in: PubMed
    Score: 0.002
  124. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006 Jun; 69(11):1945-53.
    View in: PubMed
    Score: 0.002
  125. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005 Oct; 20(10):2186-93.
    View in: PubMed
    Score: 0.002
  126. Assessment of the stability of an immunoadsorbent for the extracorporeal removal of Beta-2-microglobulin from blood. Blood Purif. 2005; 23(4):287-97.
    View in: PubMed
    Score: 0.002
  127. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004 May; 43(5):877-90.
    View in: PubMed
    Score: 0.002
  128. Osteoporosis in chronic kidney disease. Am J Kidney Dis. 2004 Mar; 43(3):566-71.
    View in: PubMed
    Score: 0.002
  129. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003 Jan; 63(1):248-54.
    View in: PubMed
    Score: 0.002
  130. Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int Suppl. 2002 Oct; (81):S23-33.
    View in: PubMed
    Score: 0.002
  131. Posttransplant bone disease: a case illustrating dramatic improvements in bone density with vitamin D replacement therapy. Transplantation. 2001 Jun 27; 71(12):1856-9.
    View in: PubMed
    Score: 0.001
  132. A novel nervous system beta subunit that downregulates human large conductance calcium-dependent potassium channels. J Neurosci. 2000 May 15; 20(10):3563-70.
    View in: PubMed
    Score: 0.001
  133. Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res. 2000 May; 15(5):927-35.
    View in: PubMed
    Score: 0.001
  134. Ectopic bone formation via rhBMP-2 delivery from porous bioabsorbable polymer scaffolds. J Biomed Mater Res. 1998 Dec 15; 42(4):491-9.
    View in: PubMed
    Score: 0.001
  135. Analysis of fracture prevalence in kidney-pancreas allograft recipients. J Am Soc Nephrol. 1998 Apr; 9(4):677-83.
    View in: PubMed
    Score: 0.001
  136. Severe hypercalcemia following neonatal liver transplantation. Miner Electrolyte Metab. 1995; 21(6):428-30.
    View in: PubMed
    Score: 0.001
  137. Acute renal failure associated with cardiac operations. A case-control study. J Thorac Cardiovasc Surg. 1989 Dec; 98(6):1107-12.
    View in: PubMed
    Score: 0.001
  138. Sarcoidosis presenting as acute renal failure during pregnancy. Am J Kidney Dis. 1988 Aug; 12(2):161-3.
    View in: PubMed
    Score: 0.001
  139. Aluminum-fluoride complexes: preclinical studies. J Environ Pathol Toxicol Oncol. 1985 Sep-Oct; 6(1):9-13.
    View in: PubMed
    Score: 0.000
  140. Determinants of tissue aluminum concentration. Am J Kidney Dis. 1981 Nov; 1(3):141-5.
    View in: PubMed
    Score: 0.000
  141. Factors affecting tissue aluminum concentration. J Dial. 1978; 2(5-6):471-81.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.